ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 256 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q4 2020. The put-call ratio across all filers is 0.26 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $42,840,207 | -19.6% | 1,201,688 | +4.1% | 0.05% | -16.4% |
| Q2 2023 | $53,272,584 | +9.6% | 1,154,836 | -4.8% | 0.06% | +8.9% |
| Q1 2023 | $48,625,901 | -8.2% | 1,212,616 | +6.0% | 0.06% | -11.1% |
| Q4 2022 | $52,994,350 | +87.0% | 1,143,972 | +67.2% | 0.06% | +70.3% |
| Q3 2022 | $28,339,000 | -16.0% | 684,344 | +21.0% | 0.04% | -11.9% |
| Q2 2022 | $33,746,000 | -35.8% | 565,645 | -21.8% | 0.04% | -22.2% |
| Q1 2022 | $52,559,000 | -15.8% | 723,758 | -2.5% | 0.05% | -11.5% |
| Q4 2021 | $62,449,000 | -3.4% | 742,641 | +3.6% | 0.06% | -12.9% |
| Q3 2021 | $64,676,000 | +14.2% | 717,108 | +20.7% | 0.07% | +14.8% |
| Q2 2021 | $56,632,000 | -11.0% | 593,943 | +6.3% | 0.06% | -20.8% |
| Q1 2021 | $63,600,000 | -39.8% | 558,579 | -26.9% | 0.08% | -45.0% |
| Q4 2020 | $105,734,000 | +37.2% | 763,805 | -18.5% | 0.14% | +13.8% |
| Q3 2020 | $77,054,000 | -15.9% | 937,514 | -20.0% | 0.12% | -22.6% |
| Q2 2020 | $91,651,000 | +117.9% | 1,171,709 | +23.8% | 0.16% | +67.4% |
| Q1 2020 | $42,053,000 | -17.1% | 946,504 | -20.3% | 0.10% | +9.2% |
| Q4 2019 | $50,738,000 | +18.7% | 1,187,963 | +18.9% | 0.09% | +8.8% |
| Q3 2019 | $42,744,000 | -55.6% | 999,166 | -34.1% | 0.08% | -55.8% |
| Q2 2019 | $96,215,000 | -25.4% | 1,515,195 | -18.5% | 0.18% | -29.3% |
| Q1 2019 | $128,944,000 | +101.5% | 1,859,052 | +26.3% | 0.26% | +68.4% |
| Q4 2018 | $64,000,000 | -33.6% | 1,471,934 | +16.5% | 0.15% | -15.6% |
| Q3 2018 | $96,453,000 | +28.4% | 1,263,466 | +29.3% | 0.18% | +15.4% |
| Q2 2018 | $75,141,000 | +53.4% | 977,505 | +1.7% | 0.16% | +38.1% |
| Q1 2018 | $48,991,000 | +34.4% | 960,792 | +22.3% | 0.11% | +29.9% |
| Q4 2017 | $36,440,000 | +30.1% | 785,694 | +49.4% | 0.09% | +20.8% |
| Q3 2017 | $28,008,000 | -11.9% | 525,878 | +2.8% | 0.07% | -15.3% |
| Q2 2017 | $31,784,000 | +19.1% | 511,740 | +30.0% | 0.08% | +14.9% |
| Q1 2017 | $26,683,000 | -5.5% | 393,667 | -1.9% | 0.07% | -11.9% |
| Q4 2016 | $28,229,000 | +796.7% | 401,487 | +1330.7% | 0.08% | +950.0% |
| Q4 2015 | $3,148,000 | +17.1% | 28,063 | +0.5% | 0.01% | 0.0% |
| Q3 2015 | $2,689,000 | – | 27,916 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 727,426 | $25,932,737 | 4.72% |
| RTW INVESTMENTS, LP | 5,405,089 | $192,691,423 | 4.07% |
| First Light Asset Management, LLC | 1,125,032 | $40,107,391 | 3.81% |
| CHI Advisors LLC | 215,000 | $7,664,750 | 3.04% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 250,052 | $8,914,354 | 3.00% |
| SPHERA FUNDS MANAGEMENT LTD. | 259,135 | $9,238,163 | 1.68% |
| Rock Springs Capital Management LP | 1,476,441 | $52,635,122 | 1.41% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 679,459 | $24,222,713 | 1.31% |
| Privium Fund Management B.V. | 115,241 | $4,108,341 | 1.22% |
| SECTOR GAMMA AS | 115,166 | $4,105,668 | 1.05% |